Quality of Life After Tailored Combined Surgery for Stage I Non–Small-Cell Lung Cancer and Severe Emphysema

Eugenio Pompeo, MD, Enrico De Dominicis, MD, Vincenzo Ambrogi, MD, Davide Mineo, MD, Stefano Elia, MD, and Tommaso C. Mineo, MD

Division of Thoracic Surgery, Policlinico Tor Vergata University, Rome, Italy

Background. We analyzed the early and long-term quality of life changes occurring in 16 patients undergoing tailored combined surgery for stage I non–small-cell lung cancer (NSCLC) and severe emphysema.

Methods. Mean age was 65 ± 5 years. All patients had severe emphysema with severely impaired respiratory function and quality of life. Tumor resection was performed with sole lung volume reduction (LVR) in 5 patients, separate wedge resection in 3 patients, segmentectomy in 2 patients, and lobectomy in 6 patients. A bilateral LVR was performed in 5 patients. Quality of life was assessed at baseline and every 6 months postoperatively by the Short-form 36 (SF-36) item questionnaire.

Results. Mean follow-up was 44 ± 21 months. All tumors were pathologic stage I. There was no hospital mortality nor major morbidity. Significant improvements occurred for up to 36 months in the general health (p = 0.02) domain and for up to 24 months in physical functioning (p = 0.02), role physical (p = 0.005), and general health (p = 0.01) SF-36 domains. Associated improvements regarded dyspnea index (−1.3 ± 0.6) forced expiratory volume in one second (+0.28 ± 0.2L), residual volume (−1.18 ± 0.5L) and 6-minute-walking test distance (+86 ± 67 m). Actuarial 5-year survival was similar to that of patients with no cancer undergoing LVRS during the same period (68% vs 82%, p = not significant).

Conclusions. Our study suggests that selected patients with stage I NSCLC and severe emphysema may significantly benefit from tailored combined surgery in terms of long-term quality of life and survival.

body spiral computed tomography (CT), postbronchodi-
lator spirometry, plethysmography, and arterial blood
gas analysis. Radiologic morphology of emphysema in-
cluding severity, heterogeneity, and asymmetric ratio of
disease was assessed according to a previously validated
visual scoring system [14]. In each patient, heterogeneity
was classified as high if a marked difference in distribu-
tion of emphysema was detected between the upper half
and lower half of the lung; it was classified as low in
patients with a homogeneous pattern of distribution.
Fiber optic bronchoscopy examination of the airway was
always performed preoperatively to confirm resectability
and provide material for cytology, cultures, and antibi-
ogram. Mediastinoscopy was never performed since no
patient had enlarged hilar or mediastinal lymph nodes at
preoperative CT study. Eligibility criteria for combined
resection were similar to those applied for a noncancer
operation. Patients with symmetric disease not requiring
lymphadenectomy was routinely performed in all pa-
tients undergoing left upper lobectomy, a tangential
resection of the pulmonary artery encompassing the
origin of the anterior segmental branch in one patient
and anterior plus superior segmental branches in an-
other 5 instances (1 sole, 1 plus unilateral LVR); segmentectomy in 2
instances (1 sole 1 plus unilateral LVR); and sole lobec-
tomy in 6 instances (2 right upper lobectomies, 1 left
lower lobectomy, and 3 left upper lobectomies). In 2
patients undergoing left upper lobectomy, a tangential
resection of the pulmonary artery encompassing the
origin of the anterior segmental branch in one patient
and anterior plus superior segmental branches in an-
other 5 instances (1 sole, 1 plus unilateral LVR). Lung volume reductions, wedge
resections, and segmentectomies were carried out by
means of video-assisted thoracoscopic surgery (VATS),
as previously described [15]. Lobectomies were carried
out by muscle sparing lateral thoracotomy following
insertion of an epidural catheter to optimize perioper-
aive anesthesia and postoperative analgesia. A radical
lymphadenectomy was routinely performed in all pa-
tients undergoing anatomical resection independently by
the type of surgical approach.

The unilateral or bilateral approach was decided on the
basis of emphysema morphology. Patients with asym-
metric emphysema, and the tumor localized in the more
emphysematous lung, underwent intentional unilateral
operation. Patients with symmetric disease not requiring
lobectomy underwent bilateral LVR±additional resec-
tion. Lobectomy was never associated with contralateral
LVR.

Postoperatively, complete functional and oncological
assessment were carried out in all patients including
spirometry, total body CT scan, and positron emission
tomographic scan.

Outcome Measures

The Medical Outcome Study Short-Form 36-item Health
Survey (SF-36) is an established generic HRQOL instru-
ment [16], which has been validated in Italy [17]. It
consists of 36 multiple-choice questions that cover 8
health concepts: physical functioning (PF), social func-
tioning (SF), role physical (RP), role emotional (RE),
vitality (VT), bodily pain (BP), mental health (MH), and
general health (GH) perception with higher scores re-
flexing a better quality of life. To test the baseline
impairment in SF-36 measures, the results of the study
group were compared with those of 16 healthy subjects.

Since the SF-36 is a generic measure of health, and not
specific for patients with impaired respiratory function,
we included as integrated clinical outcome measures also
FEV1 for airway obstruction; residual volume (RV) for
lung hyperinflation; six-minute walking test (WT) for
exercise capacity; and modified Medical Research Coun-
cil dyspnea index score for the degree of subjective
dyspnea. In addition, a self-assessment analysis of post-
operative thoracic pain was added using a four-item
questionnaire (0=no pain; 1=pain when weather chang-
es; 2=pain once a week; 3=pain every day). Finally,
survival was analyzed and compared with that of 132
patients with no cancer undergoing LVR for emphysema
during the same period.

Statistical Analysis

Group descriptive statistics are presented as means±
standard deviation (SD) and/or standard error of the
mean (SEM). Paired and unpaired data were compared
using the nonparametric Wilcoxson and Mann-Whitney
tests, respectively. Internal consistency of the question-
aire was evaluated by the Alpha Cronbach’s test (high-
est value = 1, lowest = 0). Survival was analyzed by the
Kaplan-Meier method, and differences between curves
were assessed by the Log Rank test. Results were con-
sidered significant for p less than 0.05

Results

Mean age was 65 ± 5 years. All patients fulfilled standard
inclusion criteria for LVR. In particular, all patients had
emphysema graded as severe and diffuse with disabling
symptoms despite maximized medical therapy, while no
patient had isolated giant bullous emphysema.

Among 9 patients who were on long-term oxygen
therapy, 6 had only nocturnal oxygen therapy and 3 had
continuous oxygen therapy. Internal consistency of the
SF-36 questionnaire at baseline and 6 months was satis-
factory (0.80 to 0.78) as well as the rate of answered
questions (88%). When compared with a group of healthy
people, patients with NSCLC and emphysema had a
significantly more compromised status in all baseline
SF-36 HRQOL domains but BP (Table1).

At the operation, tumor resection was accomplished by
sole LVR in 5 instances (3 bilateral and 2 unilateral);
separate wedge in 3 instances (1 sole, 1 plus unilateral
LVR, and 1 plus bilateral LVR); segmentectomy in 2
instances (1 sole 1 plus unilateral LVR); and sole lobec-
tomy in 6 instances (2 right upper lobectomies, 1 left
lower lobectomy, and 3 left upper lobectomies). In 2
patients undergoing left upper lobectomy, a tangential
resection of the pulmonary artery encompassing the
origin of the anterior segmental branch in one patient
and anterior plus superior segmental branches in an-
other, were carried out and the defect was closed with a polytetrafluoroethylene patch. There was no hospital mortality. Eight nonfatal complications including 6 prolonged air leaks and 2 transient cardiac arrhythmias occurred in 7 patients (44%). Hospital stay averaged 11.5 ± 5 days (range, 6 to 18 days).

The average size of the resected tumors was 2.4 cm (range, 1.1 to 6.0 cm). Pathologic staging showed 11 T1N0M0 and 5 T2N0M0 tumors. Between the 2 patients undergoing lobectomy with tangential resection of the pulmonary artery, both lesions were classified as T2. Histology revealed 9 adenocarcinomas, 5 squamous cell carcinomas, and 2 large cell carcinomas. Three tumors were classified as scar carcinomas. No patient underwent adjuvant therapy.

Follow-up averaged 44 ± 21 months. Sixteen patients were available at 6 months, 15 at 12 months, 13 at 24 months, and 9 at 36 months. Significant changes in SF-36 HRQOL domains at six months regarded PF (+22 ± 16, p = 0.0001), RP (+22 ± 18, p = 0.0006), GH (+15 ± 14, p = 0.0001), VT (+8 ± 7, p = 0.0006), SF (+15 ± 19, p = 0.0009), RE (+15 ± 24, p = 0.01), and MH (+3 ± 6, p = 0.01). These improvements remained significant for up to 36 months for GH only, for up to 24 months for PF and RP (Figs 1 to 3), and for up to 12 months for RE and VT.

Acute clinical improvements at 6 months regarded dyspnea index, FEV1, RV, WT, PaO2, and PaCO2. At 24 months, FEV1, RV, WT, and dyspnea index were still significantly improved, while at 36 months dyspnea index only remained significantly improved (Table 2).

At univariate analysis, neither the type of surgical approach (unilateral vs bilateral) nor the type of resection (nonanatomical versus anatomical resection) affected the clinical outcome measure results; differently, a greater improvement in FEV1 and RV was achieved in patients with higher degree of heterogeneity of the emphysema (Table 3). As far as HRQOL domains were concerned, greater improvements in PF and GH occurred in patients undergoing nonanatomical resection while greater improvements in RP and VT occurred in patients with more heterogeneous emphysema (Table 4). Finally, at 6, 12, 24, and 36 months, no difference was found in clinical measures and HRQOL domains changes when compar-

### Table 1. Baseline Scores in SF-36 HRQOL Domains in the Study Group Compared with a Healthy Control Group

<table>
<thead>
<tr>
<th>Domain</th>
<th>Study Group (n = 16) Score</th>
<th>Control Group (n = 16) Score</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF</td>
<td>39 ± 19</td>
<td>95 ± 7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RP</td>
<td>27 ± 21</td>
<td>77 ± 42</td>
<td>0.005</td>
</tr>
<tr>
<td>BP</td>
<td>89 ± 15</td>
<td>99 ± 3</td>
<td>0.1</td>
</tr>
<tr>
<td>GH</td>
<td>37 ± 16</td>
<td>71 ± 22</td>
<td>0.0004</td>
</tr>
<tr>
<td>VT</td>
<td>47 ± 21</td>
<td>95 ± 5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>SF</td>
<td>54 ± 28</td>
<td>91 ± 10</td>
<td>0.002</td>
</tr>
<tr>
<td>RE</td>
<td>50 ± 37</td>
<td>83 ± 36</td>
<td>0.02</td>
</tr>
<tr>
<td>MH</td>
<td>48 ± 22</td>
<td>91 ± 6</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

PF = physical functioning; RP = role physical; BP = bodily pain; GH = general health; VT = vitality; SF = social functioning; RE = role emotional; MH = mental health.
ing the results achieved by the 6 patients undergoing lobectomy with those of the remaining 10 patients.

Analysis of chronic pain score showed, on average, a peak at 6 months and a subsequent decrease (Fig 4). In particular, at 6, 12, 24, and 36 months there were 11, 6, 3, and 2 patients, respectively, who suffered some thoracic pain. This result was associated with a paradoxical change in BP, which was the only domain that slightly deteriorated postoperatively (Figs 1–3).

So far, no patient has died due to respiratory failure while 2 patients died due to recurrence; one after an anatomical resection and one after a nonanatomical resection. Recurrence was local in one patient and distant (brain metastases) in one other. Two patients who developed mediastinal and bone metastases, respectively, are alive with recurrence. Comparison of long-term survival curve with that of patients undergoing LVR for sole emphysema during the same period showed no difference among the groups (Fig 5).

Comment

The World Health Organization defines HRQOL as an individual perception of their position in life in the context of the cultural and value system in which they live, and in relation to their goals, expectations, standards, and concerns. Yet, measuring HRQOL has been addressed to a multidimensional subjective assessment of feelings and wellness and satisfaction, as well as perceptions of impairments and problems [18].

Patients with severe emphysema experience negative changes in mood and social behavior that are related to a variety of physiological and psychological factors. Chronic hypoxemia and dyspnea, poor activity tolerance, several types of drugs used in treatment, and frequent hospitalization may all produce detrimental changes in both social and emotional aspects of HRQOL [16].

Several different methods have been developed to assess HRQOL including the SF-36 [14], Sickness Impact Profile [19], Nottingham Health Profile [20], St. George’s Chronic Respiratory Disease Questionnaire [21], and the European Organization For Research and Treatment of Cancer quality of life questionnaire [13].

The SF-36 has been widely used as a general health status instrument [16]. In addition, it has also been employed to assess changes in HRQOL after LVR [4, 5, 20]. Cooper and colleagues [20] and Moy and colleagues [4] reported significant improvements in SF-36 HRQOL

Table 2. Baseline Clinical Measures and Postoperative Results

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline (N = 16)</th>
<th>6 Months (N = 16)</th>
<th>12 Months (N = 16)</th>
<th>24 Months (N = 13)</th>
<th>36 Months (N = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DI (score)</td>
<td>3.2 ± 0.6</td>
<td>1.9 ± 0.7*</td>
<td>1.8 ± 0.9*</td>
<td>2.1 ± 0.6*</td>
<td>2.2 ± 0.8*</td>
</tr>
<tr>
<td>FEV₁ (L)</td>
<td>0.92 ± 0.5</td>
<td>1.20 ± 0.4*</td>
<td>1.20 ± 0.4*</td>
<td>1.06 ± 0.3*</td>
<td>1.00 ± 0.4</td>
</tr>
<tr>
<td>FVC (L)</td>
<td>2.6 ± 0.7</td>
<td>2.81 ± 0.6*</td>
<td>2.85 ± 0.6*</td>
<td>2.78 ± 0.6</td>
<td>2.78 ± 0.5</td>
</tr>
<tr>
<td>RV (L)</td>
<td>5.2 ± 0.7</td>
<td>3.99 ± 0.7*</td>
<td>4.13 ± 0.9*</td>
<td>4.20 ± 0.8*</td>
<td>4.50 ± 1.0*</td>
</tr>
<tr>
<td>TLC (L)</td>
<td>8.3 ± 0.9</td>
<td>7.4 ± 1.0</td>
<td>7.6 ± 1.0</td>
<td>7.5 ± 0.9</td>
<td>7.8 ± 0.7</td>
</tr>
<tr>
<td>PaO₂ (mm Hg)</td>
<td>68 ± 6</td>
<td>70 ± 7*</td>
<td>70 ± 6*</td>
<td>69 ± 6</td>
<td>66 ± 8*</td>
</tr>
<tr>
<td>PaCO₂ (mm Hg)</td>
<td>40 ± 2</td>
<td>39 ± 2*</td>
<td>39 ± 2</td>
<td>40 ± 3</td>
<td>41 ± 4</td>
</tr>
<tr>
<td>DCO (%)</td>
<td>40 ± 21</td>
<td>40 ± 17</td>
<td>43 ± 17</td>
<td>39 ± 17</td>
<td>38 ± 14*</td>
</tr>
<tr>
<td>WT (m)</td>
<td>355 ± 144</td>
<td>441 ± 87*</td>
<td>465 ± 88*</td>
<td>452 ± 62*</td>
<td>416 ± 87</td>
</tr>
<tr>
<td>Oxygen use (patients)</td>
<td>9</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Steroid use (patients)</td>
<td>16</td>
<td>4*</td>
<td>6*</td>
<td>7*</td>
<td>7</td>
</tr>
</tbody>
</table>

Preoperative versus postoperative result: ∗P < 0.02; ∗∗P < 0.05.

DI = modified medical research council dyspnea index; FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity; RV = residual volume; PaO₂ = arterial oxygen tension; PaCO₂ = arterial carbon dioxide tension; DCO = diffusing capacity for carbon monoxide; WT = six-minute walking test.

Table 3. Effect of Surgical Approach, Type of Resection and Degree of Heterogeneity of the Emphysema on Pre- Versus 6-Monthly Postoperative Changes in Clinical Outcome Measures

<table>
<thead>
<tr>
<th>Clinical Outcome Measure (Unilateral Versus Bilateral)</th>
<th>Type of Approach (Nonanatomical Versus Anatomical)</th>
<th>Heterogeneity of Emphysema (Low Versus High)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N = 11 N = 5</td>
<td>N = 8 N = 8</td>
<td>N = 8 N = 8</td>
</tr>
<tr>
<td>ΔFEV₁ (L)</td>
<td>0.26 ± 0.2</td>
<td>0.33 ± 0.2</td>
</tr>
<tr>
<td>ΔRV (L)</td>
<td>1.1 ± 0.4</td>
<td>1.3 ± 0.6</td>
</tr>
<tr>
<td>ΔWT (m)</td>
<td>88 ± 58</td>
<td>103 ± 64</td>
</tr>
<tr>
<td>ΔDI (score)</td>
<td>1.2 ± 0.6</td>
<td>1.4 ± 0.5</td>
</tr>
</tbody>
</table>

Intergroup difference, *P = 0.06; *∗P < 0.04; ∗∗P < 0.001.

DI = modified medical research council dyspnea index; FEV₁ = forced expiratory volume in one second; RV = residual volume; WT = six-minute walking test. 
Table 4. Effect of Surgical Approach, Type of Resection and Degree of Heterogeneity of the Emphysema on Pre- Versus 6-
Monthly Postoperative Changes in HRQOL Measures

<table>
<thead>
<tr>
<th>SF-36 QOL Domain</th>
<th>Type of approach (Unilateral Versus Bilateral)</th>
<th>N = 11</th>
<th>N = 5</th>
<th>Type of Resection (Nonanatomical Versus Anatomical)</th>
<th>N = 8</th>
<th>N = 8</th>
<th>Heterogeneity of Emphysema (Low Versus High)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ΔPF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔRP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔBP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔGH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔVT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔSF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔRE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔMH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Intergroup difference, * P = 0.06; † P < 0.04; §P < 0.001.

PF = physical functioning; RP = role physical; BP = bodily pain; GH = general health; VT = vitality; SF = social functioning; RE = role emotional; MH = mental health.

domains. Yet, Hamacher and colleagues [5] reported that improvements in PF, RP, VT, SF, and MH SF-36 domains occurred early after thoracoscopic LVR and lasted for up to 24 months. More recently, Yusen and colleagues [7] reported that a significant clinical change in PF, which has probably the most relevance for patients with emphysema, occurred at 6 months, 3 years, and 5 years, in 90%, 69%, and 57% of the patients, respectively. Finally, Goldstein and colleagues [6] reported that LVR resulted in important benefits in disease-specific quality of life compared with medical management, which remained sustained at 12 months after treatment. Yet, in the same series, no difference between patients treated bilaterally or unilaterally was found for any of the outcome measures at baseline and following surgery.

As far as the effects of lung cancer in HRQOL are concerned, they tend to deteriorate significantly with increasing extent of disease [22] and are mainly addressed to cancer symptoms such as chronic pain, weakness, and tiredness. These symptoms are usually associated with recurrent disease, which is thus the most important determinant of postoperative HRQOL. Dales and colleagues [12] reported that HRQOL deteriorated early after thoracotomy and returned to preoperative status since 6 months postoperatively. Zieren and colleagues [11] also reported that the postoperative deterioration of HRQOL was mainly affected by restrictions related to physical activities, job and household tasks, and disease symptoms, while limitations in emotional and social domains were less frequent and less severe. In addition, Nou and Aberg [23] reported that HRQOL was better in 5-year surviving patients and poorer in those receiving nonresectional thoracotomy.

We assumed that in this series, the main factors influencing HRQOL were the degree of functional disability, the degree of postoperative improvements, and the occurrence of thoracic pain due to the early cancer stage.

Fig 4. Chronic pain scores at 6, 12, 24, and 36 months; p values refer to comparisons with the 6-month result.

Fig 5. Cumulative survival curve compared with that of 132 patients with sole emphysema undergoing lung volume reduction during the study period.
and the absence of preoperative cancer-related symptoms. Nonetheless, the presence of lung cancer can affect HRQOL by influencing the surgical strategy, which must be guided not only by the distribution of the emphysematous target areas but also by the tumor characteristics and localization.

The main finding of our study is that rigorously selected patients with end-stage emphysema and stage I NSCLC can significantly benefit from tailored combined surgery in terms of both HRQOL domains changes and long-term survival. As a matter of fact, significant improvements occurred early after surgery in several SF-36 HRQOL domains and remained sustained for up to 36 months. These were accompanied by significant improvements in respiratory function measures, exercise capacity, and subjective dyspnea. A significantly better result was achieved in PF and GH domains in patients undergoing nonanatomical resections compared with those undergoing anatomical resections, while improvements in RP and VT domains were greater in patients with more heterogeneous emphysema. Yet, patients with a high degree of heterogeneity had a greater improvement in FEV1, confirming that heterogeneous distribution of disease is one of the main prerequisites predicting maximal benefit in LVR [20]. In addition, comparison of unilaterally versus bilaterally treated patients showed no difference in postoperative HRQOL domains and clinical improvements. Though the small cohort clearly limits definitive inferences, our results corroborate the previous finding that in patients with asymmetric emphysema, benefit of unilateral LVR can compare to that of the bilateral treatment. In addition, our results confirm that postoperative thoracic pain is not a negligible problem in patients undergoing thoracic surgery by either VATS or thoracotomy and can negatively affect HRQOL [24].

Among 8 patients who have undergone anatomical resections, 6 underwent lobectomy and, in 2 of these, a tangential resection of the pulmonary artery was performed to avoid a pneumonectomy. Satisfactory improvements in respiratory function measures, exercise capacity, and subjective dyspnea had already been reported after lobectomy for NSCLC in emphysema patients by De Meester and colleagues [9] and by Edwards and colleagues [10] while no data existed so far on HRQOL changes. In a recent series on LVR [7], lobectomies were carried out in patients with a severely emphysematous target lobe but contralateral LVR was always added. Although we acknowledge that bilateral treatment is the standard of care in patients undergoing LVR, several reasons led us to prefer sole lobectomy. In fact, even in those patients in whom emphysema is prevailing in one lobe, some preserved tissue is almost always present and is sacrificed if lobectomy is performed. Thus, in patients undergoing lobectomy, we preferred to avoid contralateral LVR to limit the risk of resection of a further amount of preserved lung tissue, which could eventually lead to pulmonary hypertension and cor pulmonale. Moreover, with unilateral operation overall operative time is significantly shorter than that required for a bilateral procedure including lobectomy. Finally, our recent finding that a staged bilateral LVR can result in more prolonged benefit than one-stage bilateral treatment can suggest to delay contralateral LVR until the benefit achieved with unilateral procedure is lost [25].

In fact, meaningful improvements in FEV1, RV, WT, dyspnea index, and HRQOL SF-36 domains occurred also in patients treated by lobectomy and more complex tissue sparing resections, demonstrating that they can be safely carried out in severely emphysematous patients provided that the tumor is contained in an emphysematous lobe.

It is thus conceivable that lobectomy behaved as a lobar LVR, which exerted a bilateral effect on chest wall mechanics possibly due to the interdependence between the hemithoraces, the compliance of the lungs, and the mobility of the mediastinum.

The 68% 5-year survival rate in this series is highly satisfactory if one considers that the expected 5-year survival in unselected patients undergoing lobectomy for stage I NSCLC ranged between 67% for stage IA and 57% for stage IB [26], whereas 3-year survival of patients undergoing LVR for emphysema is between 65% and 80% [27, 28].

Hypothetical reasons to explain such a satisfactory outcome include, first, the strict radiologic surveillance of patients with emphysema that can help discover early stage asymptomatic tumors. Second, the reduced vascular and lymphatic peritumoral network often found in severely emphysematous lungs could limit the probability of an early tumor spread. This hypothesis is supported not only by our overall survival rate but also by the finding that no positive lymph nodes were found among eight patients undergoing radical lymphadenectomy. This is in contrast with the common finding that nodal occult metastases can be detected in up to 20.4% of the patients with peripheral tumors of 2.0 cm or less in diameter [29]. For these reasons, although lobectomy still remains our preferred type of resection for stage I NSCLC, wide wedge resections as well revealed an acceptable oncologic treatment for these particular patients.

We conclude that by a rigorous preoperative evaluation and a tailored surgical strategy including nonanatomical, anatomical, and more complex tissue sparing resections based on emphysema morphology and the tumor characteristics, significant improvements in HRQOL domains and highly satisfactory long-term survival can be achieved in patients with stage I NSCLC and severe emphysema.

This study was supported partially by the Ministero dell’Università e della Ricerca (MIVR) (Grant COFIN #9906274194-06 and 2001061131-001); by the Consiglio Nazionale delle Ricerche (Single Project 2002 CNR CU100935CT26), and by the Progetto Ministero della Salute-Regione Lazio 2002.

References


